Pascal Deschatelets News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pascal deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pascal Deschatelets Today - Breaking & Trending Today

Frazier Life Sciences Management L.P. Acquires 271,122 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Frazier Life Sciences Management L.P. lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 44.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 885,165 shares of the company’s stock after acquiring an additional 271,122 shares during the […] ....

Mark Jeffrey Delong , Pascal Deschatelets , Quarter For Apellis Pharmaceuticals , Securities Exchange Commission , Woodward Diversified Capital , News Ratings For Apellis Pharmaceuticals Daily , Hc Advisors , Apellis Pharmaceuticals Price Performance , Jpmorgan Chase Co , Apellis Pharmaceuticals , Apellis Pharmaceuticals Profile , Covestor Ltd , Frazier Life Sciences Management , Exchange Commission , Apellis Pharmaceuticals Inc , Whittier Trust Co , Asset Management Group , Needham Company , Free Report , Management Group , Diversified Capital , Whittier Trust , Get Free Report , Apellis Pharmaceuticals Daily ,

KPP Advisory Services LLC Raises Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

KPP Advisory Services LLC boosted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 17.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,196 shares of the company’s stock after purchasing an additional 1,675 shares during the quarter. KPP Advisory Services LLC’s […] ....

Timothy Eugene Sullivan , Pascal Deschatelets , Apellis Pharmaceuticals Stock Down , Norges Bank , Needham Company , Wells Fargo Company , Apellis Pharmaceuticals , Advisory Services , Fiera Capital Corp , Polar Capital Holdings Plc , Insider Activity At Apellis Pharmaceuticals , Jpmorgan Chase Co , News Ratings For Apellis Pharmaceuticals Daily , Securities Exchange Commission , Kpp Advisory Services , Apellis Pharmaceuticals Inc , Quarter For Apellis Pharmaceuticals , Free Report , Capital Holdings Plc , Capital Corp , Nova Scotia , Exchange Commission , Eugene Sullivan , Pharmaceuticals Stock Down , Get Free Report , Visit Holdingschannel ,

Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $92.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 123.79% from the company’s previous close. […] ....

Pascal Deschatelets , Robertw Baird , Timothy Eugene Sullivan , Polar Capital Holdings Plc , Apellis Pharmaceuticals Inc , Apellis Pharmaceuticals Stock Performance , Norges Bank , Vanguard Group Inc , Jefferies Financial Group , News Ratings For Apellis Pharmaceuticals Daily , Apellis Pharmaceuticals , Jpmorgan Chase Co , Securities Exchange Commission , Wells Fargo Company , Analyst Recommendations For Apellis Pharmaceuticals , Pricet Rowe Associates Inc , Get Free Report , Financial Group , Exchange Commission , Eugene Sullivan , Capital Holdings Plc , Apellis Pharmaceuticals Daily ,

Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $48.00 at Wells Fargo & Company

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock. Other analysts also recently issued reports about the stock. Wedbush dropped their price objective […] ....

Robertw Baird , Pascal Deschatelets , Cedric Francois , Asset Management Group , Apellis Pharmaceuticals Price Performance , Needham Company , News Ratings For Apellis Pharmaceuticals Daily , Apellis Pharmaceuticals Company Profile , Apellis Pharmaceuticals , Wells Fargo Company , Apellis Pharmaceuticals Inc , Covestor Ltd , Analyst Recommendations For Apellis Pharmaceuticals , Financial Wealth Managment , Free Report , Wells Fargo , Moderate Buy , Get Free Report , Management Fondsmaeglerselskab , Management Group , Apellis Pharmaceuticals Daily ,

Wells Fargo & Company Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $48.00

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $48.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an equal weight rating on the stock. Other equities analysts have also recently issued research reports about the stock. […] ....

Robertw Baird , Pascal Deschatelets , Cedric Francois , Needham Company , Covestor Ltd , Wells Fargo Company , Apellis Pharmaceuticals Stock Performance , Securities Exchange Commission , Financial Wealth Managment , Apellis Pharmaceuticals , Woodward Diversified Capital , Analyst Recommendations For Apellis Pharmaceuticals , News Ratings For Apellis Pharmaceuticals Daily , Apellis Pharmaceuticals Inc , Jpmorgan Chase Co , Hedge Funds Weigh In On Apellis Pharmaceuticals , Asset Management Group , Free Report , Wells Fargo , Moderate Buy , Get Free Report , Exchange Commission , Management Fondsmaeglerselskab , Management Group , Apellis Pharmaceuticals Daily ,